Become A Member

Triple Negative Receptor Status in Patients Diagnosed with Carcinoma Breast

Shabbir Ahmed¹, Bushra Ghulam¹, Verdah Azam¹, Sumta Khan¹, Sumera Nighat² and Tahira Atiq²

ABSTRACT

Objective: To evaluate the frequency of triple negative receptor status in patients diagnosed with breast carcinoma.

Study Design: Cross sectional study

Place and Duration of Study: This study was conducted at the Surgery Department of Nishtar Hospital, Multan from July 2022 to June 2023 in duration of one year.

Methods: A total of 180 patients having age 30-60 years who were presented with suspicion of carcinoma breast were enrolled in study. Data was evaluated and analyzed on IBM SPSS version 23. Chi-square with probability value 0.05 was applied to see association among variables. Demographic and clinical data (age, family history of TNBC, menopausal status and TNBC presence) were presented as mean standard deviation and frequency percentages.

Results: Mean age and size of tumor were 43.46 ± 8.38 and 2.52 ± 0.025 respectively. Triple negative receptor status (TNBC) is the main outcome variable of study which was 21.2% was having TNBC. Menopausal status was positive in majority of patients 77.7%, family history of TNBC was present in 20% patients. Patients were classified in 3 groups according to their status of age, 38.8% patients were having age between 30-40 years, 74 (40.4%) were between 41-50 years and 20.8% between age 51-60 years.

Conclusion: Breast cancer is a concerning issue, especially for younger women. TNBC is a estrogen, HER2 and progesterone receptor lacking subtype of breast cancer.

Key Words: Carcinoma breast, Ductal carcinoma in situ, Metastasis, Triple negative breast cancer.

Citation of article: Ahmed S, Ghulam B, Azam V, Khan S, Nighat S, Atiq T. Triple Negative Receptor Status in Patients Diagnosed with Carcinoma Breast. Med Forum 2024;35(10):7-10. doi:10.60110/medforum.351002.